Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition.

Tytuł:
An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition.
Autorzy:
Muller D; Division of oncogenetic, Department of Biology and Pathology, Regional Cancer Centre Paul Strauss, BP30042, 67065 Strasbourg, France. />Rouleau E
Schultz I
Caputo S
Lefol C
Bièche I
Caron O
Noguès C
Limacher JM
Demange L
Lidereau R
Fricker JP
Abecassis J
Źródło:
BMC medical genetics [BMC Med Genet] 2011 Sep 22; Vol. 12, pp. 121. Date of Electronic Publication: 2011 Sep 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, [2000-
MeSH Terms:
Exons*
Genes, BRCA2*
Sequence Deletion*
Breast Neoplasms/*genetics
Base Sequence ; Comparative Genomic Hybridization ; DNA Primers/genetics ; DNA, Neoplasm/genetics ; Female ; Gene Rearrangement ; Genetic Predisposition to Disease ; Genetic Testing ; Germ-Line Mutation ; Humans ; Ovarian Neoplasms/genetics ; Pedigree ; Point Mutation ; Polymerase Chain Reaction
References:
Oncogene. 2002 Jun 13;21(26):4171-5. (PMID: 12037674)
Cell. 2003 Nov 26;115(5):523-35. (PMID: 14651845)
Nature. 1997 Apr 24;386(6627):772-3. (PMID: 9126734)
Mol Cell. 2006 Jun 23;22(6):719-729. (PMID: 16793542)
Hum Mol Genet. 2002 Nov 1;11(23):2805-14. (PMID: 12393792)
Clin Genet. 2007 Sep;72(3):199-207. (PMID: 17718857)
Int J Clin Exp Pathol. 2008 Jan 01;1(4):343-51. (PMID: 18787609)
J Med Genet. 2006 Sep;43(9):e49. (PMID: 16950820)
J Clin Oncol. 2007 May 20;25(15):2027-34. (PMID: 17513806)
Hum Mutat. 2005 Sep;26(3):284. (PMID: 16088935)
Clin Cancer Res. 2004 Sep 1;10(17):5785-91. (PMID: 15355907)
Hum Mutat. 2002 Sep;20(3):218-26. (PMID: 12203994)
Breast Cancer Res Treat. 2011 Jun;127(3):671-9. (PMID: 20652400)
Breast Cancer Res Treat. 2009 Sep;117(1):215-7. (PMID: 18853249)
Cancer Res. 2004 Nov 15;64(22):8143-7. (PMID: 15548676)
J Med Genet. 2008 Jul;45(7):438-46. (PMID: 18424508)
J Clin Oncol. 2007 Apr 10;25(11):1329-33. (PMID: 17416853)
Oncogene. 2000 Sep 7;19(38):4441-5. (PMID: 10980621)
Genes Chromosomes Cancer. 1999 Aug;25(4):407-9. (PMID: 10398438)
Genes Chromosomes Cancer. 1999 Dec;26(4):381-2. (PMID: 10534775)
N Engl J Med. 2004 Mar 18;350(12):1252-3. (PMID: 15028830)
Pathol Biol (Paris). 2006 May;54(4):230-50. (PMID: 16632260)
Oncol Rep. 1999 Mar-Apr;6(2):437-40. (PMID: 10023017)
Breast Cancer Res. 2004;6(5):201-3. (PMID: 15318925)
Breast Cancer Res Treat. 2009 Aug;116(3):617-8. (PMID: 18633700)
Hum Mutat. 2009 Nov;30(11):1543-50. (PMID: 19795481)
Genes Chromosomes Cancer. 1999 Mar;24(3):207-12. (PMID: 10451700)
Breast Cancer Res Treat. 2009 Mar;114(1):31-8. (PMID: 18363094)
Cancer Res. 1999 Jun 1;59(11):2546-50. (PMID: 10363970)
Cancer Sci. 2004 Nov;95(11):866-71. (PMID: 15546503)
Cancer Res. 2003 Apr 1;63(7):1449-53. (PMID: 12670888)
Cancer Res. 2005 Jan 15;65(2):417-26. (PMID: 15695382)
J Med Genet. 2005 Oct;42(10):e64. (PMID: 16199546)
Cancer Res. 1998 Apr 1;58(7):1372-5. (PMID: 9537232)
Mol Cancer Res. 2009 Jul;7(7):1110-8. (PMID: 19584259)
Nat Genet. 2001 Jan;27(1):55-8. (PMID: 11137998)
J Clin Oncol. 2007 Nov 1;25(31):5035-6; author reply 5036-8. (PMID: 17971607)
J Biol Chem. 2003 Sep 19;278(38):35979-87. (PMID: 12815053)
Am J Hum Genet. 2004 Oct;75(4):535-44. (PMID: 15290653)
Substance Nomenclature:
0 (DNA Primers)
0 (DNA, Neoplasm)
Entry Date(s):
Date Created: 20110924 Date Completed: 20111202 Latest Revision: 20211020
Update Code:
20240104
PubMed Central ID:
PMC3198910
DOI:
10.1186/1471-2350-12-121
PMID:
21939546
Czasopismo naukowe
Background: Germ-line mutations in the BRCA1 and BRCA2 genes are major contributors to hereditary breast/ovarian cancer. Large rearrangements are less frequent in the BRCA2 gene than in BRCA1. We report, here, the first total deletion of exon 3 in the BRCA2 gene that was detected during screening of 2058 index cases from breast/ovarian cancer families for BRCA2 large rearrangements. Deletion of exon 3, which is in phase, does not alter the reading frame. Low levels of alternative transcripts lacking exon 3 (Δ3 delta3 transcript) have been reported in normal tissues, which raises the question whether deletion of exon 3 is pathogenic.
Methods: Large BRCA2 rearrangements were analysed by QMPSF (Quantitative Multiplex PCR of Short Fluorescent Fragments) or MLPA (Multiplex Ligation-Dependent Probe Amplification). The exon 3 deletion was characterized with a "zoom-in" dedicated CGH array to the BRCA2 gene and sequencing. To determine the effect of exon 3 deletion and assess its pathogenic effect, three methods of transcript quantification were used: fragment analysis of FAM-labelled PCR products, specific allelic expression using an intron 2 polymorphism and competitive quantitative RT-PCR.
Results: Large rearrangements of BRCA2 were detected in six index cases out of 2058 tested (3% of all deleterious BRCA2 mutations). This study reports the first large rearrangement of the BRCA2 gene that includes all of exon 3 and leads to an in frame deletion of exon 3 at the transcriptional level. Thirty five variants in exon 3 and junction regions of BRCA2 are also reported, that contribute to the interpretation of the pathogenicity of the deletion. The quantitative approaches showed that there are three classes of delta3 BRCA2 transcripts (low, moderate and exclusive). Exclusive expression of the delta3 transcript by the mutant allele and segregation data provide evidence for a causal effect of the exon 3 deletion.
Conclusion: This paper highlights that large rearrangements and total deletion of exon 3 in the BRCA2 gene could contribute to hereditary breast and/or ovarian cancer. In addition, our findings suggest that, to interpret the pathogenic effect of any variants of exon 3, both accurate transcript quantification and co-segregation analysis are required.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies